GlassScriptPhysician profile
Niranjan Gunasekaran
NPI 1598108185
$4,942.31
in general payments reported to CMS, 2019-2025
28 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $19.80 · 2022: $225 · 2023: $1,305 · 2024: $993 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,917 · Education: $54.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,916.88 |
| Education | $54.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $502.79 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Enterprises LLC | $492.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.80 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $308.59 | 2023-2025 | Acthar, Terlivaz |
| Amgen INC. | $296.07 | 2023-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $284.83 | 2022-2025 | Veltassa, Korsuva |
| Boston Scientific Corporation | $276.07 | 2022-2023 | Watchman Access System |
| Ani Pharmaceuticals, INC. | $271.01 | 2023-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $221.87 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $218.27 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $191.23 | 2023-2025 | |
| Novo Nordisk INC | $164.74 | 2024-2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $155.00 | 2019-2025 | Vafseo |
| Travere Therapeutics, INC. | $145.53 | 2023-2025 | |
| Ardelyx, INC. | $144.52 | 2024-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $136.59 | 2023 | |
| Janssen Pharmaceuticals, INC | $128.88 | 2023 | Xarelto |
| Fresenius USA Marketing, INC. | $127.84 | 2022-2024 | Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.09 | 2024-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $92.24 | 2024-2025 | |
| Renalytix Ai, INC. | $69.04 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Alexion Pharmaceuticals, INC. | $60.90 | 2024-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $58.71 | 2023-2025 | Lupkynis |
| Fresenius USA Manufacturing, INC. | $47.09 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.16 | 2022-2023 | Gattex |
| Opko Pharmaceuticals, LLC | $35.85 | 2025 | Rayaldee |
| Shield Therapeutics INC | $24.40 | 2025 | |
| Lilly USA, LLC | $14.49 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niranjan Gunasekaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.